Episode Details

Belite Bio (BLTE) Q2 2026 — Q2 2026 (quarter ended June 30). Belite is a foreign private issuer - no 10-Q, the quarter is a 6-K. It cleared EDGAR 9:50pm ET August 12, AFTER the close, so August 13 IS the reaction session: opened dead flat, closed -7.07 pct on 3.04x volume. On August 11 the FDA accepted the first New Drug Application ever filed in Stargardt disease and granted Priority Review. The stock closed up 0.77 pct. Thirty hours later Belite printed the quarter and the stock fell 7.07 pct on triple volume. THE CALL: HOLD (3/5, MEDIUM - THE APPROVAL IS PRICED, THE LABEL IS NOT WRITTEN) — base-case value ~$136.18 vs ~$162.80 today. KEY METRICS: - CALL: HOLD, 3/5. Fair value USD136.18 against the USD162.80 close, -16.4 pct. Bear USD52.96 / base USD139.29 / bull USD213.17. Risk-adjusted NPV, every assumption stated: 46 pct peak operating margin, 11x exit multiple, 8 years to peak, 11 pct discount rate, 85 pct odds of approval. - THE PRINT: net loss USD28.4M against USD16.3M, GAAP loss per share USD0.70 against a USD0.73 consensus. That three-cent difference is about USD1.2M of spending timing on 40,182,310 weighted shares - not operating news. Six-month net loss USD55.4M against USD30.6M. There is no revenue line. - WHAT ACTUALLY MOVED IT: cash selling and administrative expense, excluding share compensation, went USD1.3M to USD10.9M - 8.2 TIMES - in twelve months, and USD2.8M to USD16.6M across the half. Cash operating expense rose 181.8 pct to USD28.1M. Share compensation FELL, USD7.6M to USD6.8M. - THE ASYMMETRY: the FDA accepted the first NDA ever filed in Stargardt disease, with PRIORITY REVIEW, after the close on August 11. The August 12 reaction session closed +0.77 pct. The Q2 results landed after the close on August 12, and August 13 opened dead flat and closed -7.07 pct. - BALANCE SHEET: USD279.9M of cash plus USD500.1M of US Treasury bills and notes is USD780.0M, 98.5 pct of total assets, against USD14.9M of total liabilities and no debt. Liquid assets fell only USD18.6M in the quarter from USD798.6M. About 9 years of runway on the USD21.6M non-GAAP loss. - THE ASSET: tinlarebant, a once-daily oral RBP4 antagonist. Phase 3 DRAGON, 104 subjects aged 12 to 20 over 24 months, cut atrophic lesion growth 35.7 pct versus placebo. PDUFA February 12 2027. DRAGON II enrolled 73; PHOENIX in geographic atrophy enrolled 530, with an interim analysis ahead. - WHAT THE TAPE REQUIRES: at USD162.80 the enterprise value is USD5.79bn, or USD109,269 per US Stargardt patient against a company estimate of 53,000. That price needs USD3.51bn of peak sales, 20.5 pct above our base case - roughly 14,049 patients at USD185,000 a year, 26.5 pct of the pool. What to watch: UP: an approved label on February 12 2027 covering adults rather than the 12-to-20 trial population, or a positive PHOENIX interim in geographic atrophy. DOWN: a label written to the DRAGON population, payer resistance to an imaging endpoint, or a commercial build sized for patients who never come. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision. Learn investing free in the Charged Alpha app: https://chargedalpha.com/app?source=youtube&ref=video Educational only. Not financial advice.